N-Zyme Biomedical Begins Phase 2 Trial of First Pepsin Inhibitor for Reflux Disease
Company advancing a first-in-class approach to targeting pepsin, with the potential to redefine the standard of care; recently granted patents from the U.S. Patent and Trademark Office and Japan Patent Office, strengthening its intellectual property position
N-Zyme Biomedical, a clinical-stage biotechnology company developing a novel class of therapeutics targeting pepsin in reflux disease, today announced the initiation of its Phase 2 clinical trial to evaluate its lead pepsin inhibitor candidate for the treatment of laryngopharyngeal reflux (LPR).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610221836/en/ Attendees gather at N-Zyme Biomedical's Phase 2 Clinical Trial Launch Celebration at the Medical College of Wisconsin.
The trial represents a key milestone in the development of what is believed to be the first therapeutic approach specifically designed to inhibit pepsin, a primary driver of tissue damage and symptoms in reflux disease.
